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0.005) decreased from 66.9 (53.6–80.8) to 9.4 (4.6–26.0) and 
from 5.1 (3.0–8.4) to 1.1 (0.6–3.2), and then recovered toward 
baseline. Blood pressure and lipids significantly decreased 
on treatment, without changes in inulin-measured GFR or 
para-aminohippuric-measured RPF. After recovery, one pa-
tient refused to enter the extension, one with severe renal 
insufficiency at baseline reached ESRD, and seven retained 
normal serum creatinine until the end of the study. At the 
final visit, three were microalbuminuric and one was normo-
albuminuric. Treatment was well tolerated.  Conclusion: The 
Remission Clinic approach safely ameliorated albuminuria, 
blood pressure, lipids, and glomerular selectivity in AS pa-
tients and halted long-term progression in those without re-
nal insufficiency to start with.  © 2015 S. Karger AG, Basel 
 Introduction 
 Alport syndrome (AS) is a hereditary type IV collagen 
disease, which in approximately 50% of untreated male 
patients progresses to ESRD by the age of 20 years  [1] . 
There is no specific treatment for AS nephropathy. In 
animals with autosomal-recessive AS such as COL4A3 
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 Abstract 
 Background/Aims: Combined ACE inhibitor, angiotensin-
receptor-blocker, non-dihydropyridine calcium-channel-
blocker, and statin therapy (Remission Clinic) reduced pro-
teinuria and halted progression in non-diabetic nephropa-
thies, but their efficacy in Alport syndrome (AS) nephropathy 
is unknown.  Methods: From February 2004 to September 
2007, we included nine albuminuric AS adults with creati-
nine clearance >20 ml/min/1.73 m 2 in a single-center, open-
label, prospective, off-on-off academic study. After the 
1-month wash-out from RAS inhibition (Run-in), patients en-
tered the 4-month, add-on, treatment period with benaz-
epril (10–20 mg/day), valsartan (80–160 mg/day), diltiazem 
(60–120 mg/day), and fluvastatin (40–80 mg/day) followed 
by the 1-month wash-out (Recovery). The primary outcome 
was albuminuria at month 4. After recovery, patients were 
kept on the Remission Clinic protocol and followed until July 
2014 (Extension).  Results: The median (IQR) albuminuria 
progressively declined from 657.7 (292.7–1,089.6) μg/min at 
baseline to 71.4 (21.7–504.9) μg/min at treatment end (p = 
0.009) and raised to 404.3 (167.9–446.8) μg/min after recov-
ery. Albumin and IgG fractional clearances significantly (p  ≤ 
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knockout mice, preemptive Angiotensin-Converting-
Enzyme (ACE) inhibition with ramipril therapy started 
at four weeks of age prevented renal fibrosis, postponed 
uremia, and doubled the lifespan  [2]; whereas later in-
tervention started after the onset of proteinuria failed to 
appreciably affect disease progression and kidney and 
mice survival  [2] . Consistently, data from the European 
Alport Registry study  [3] showed that early ACE inhibi-
tor therapy started at the stage of isolated hematuria or 
microalbuminuria normalized urinary albumin and 
slowed down to a very significant extent progression to 
ESRD in patients with the disease. Conversely, when 
ACE inhibitor therapy was initiated after the onset of 
proteinuria or renal insufficiency, proteinuria declined 
only partially and transiently, and it marginally affected 
renal outcomes of patients who progressed to ESRD by 
the age of 25–40 years. Their untreated relatives required 
dialysis therapy at a median age of 22 years  [3] . Thus, 
both mouse and human data converge to indicate that 
early treatment allows preventing the onset and progres-
sion of chronic kidney disease (CKD); whereas more ef-
fective intervention strategies are needed to halt progres-
sion in AS patients with established proteinuria.
 Evidence is available that an integrated treatment with 
different medications that lower proteinuria by multiple 
and potentially synergistic mechanisms might help in 
achieving this target. Animal  [4] and human  [5] studies 
have consistently found that ACE inhibitors and Angio-
tensin Receptor Blockers (ARBs) share similar antipro-
teinuric and renoprotective effects. The antiproteinuric 
effect can be increased by 50–60% if the two drugs are 
used in combination  [6, 7] , and combination therapy may 
stabilize and even improve kidney function in patients 
with non-diabetic CKD and severe proteinuria who are 
otherwise predicted to progress to ESRD in a few years 
while on ACE inhibitor monotherapy  [8, 9] . Non-dihy-
dropyridine calcium channel blockers (ndCCBs) and 
 hydroxymethyl-glutaryl CoA (HMGCoA) inhibitors 
(statins) have also been reported to reduce proteinuria 
regardless of their effect on BP  [10] or serum lipids  [11] , 
respectively, and some data suggested that ndCCBs could 
also slow renal disease progression over time  [10] . A mul-
timodal, individually tailored, intervention strategy, in-
cluding HMGCoA inhibitors, added on dual RAS block-
ade to target urinary proteins blunted glomerulosclerosis 
and prevented progression to ESRD in rats with severe 
proteinuric CKD  [12] . A similar strategy – the Remission 
Clinic program – was implemented to target urinary pro-
teins in humans by ACE inhibitors and ARBs up-titrated 
to maximum tolerated doses, plus a statin and an ndCCB 
 [8] . This individually tailored approach, in addition to 
achieving remission and even regression of proteinuria, 
almost fully prevented kidney failure in 56 patients with 
residual nephrotic-range proteinuria despite ACE inhib-
itor therapy  [8] . Thus, in this study, we sought to investi-
gate the antiproteinuric and long-term renoprotective ef-
fect of the Remission Clinic approach in AS patients at 
increased risk of renal disease progression, and verified 
whether and to what extent the treatment regimen was 
tolerated in this context.
 Patients and Methods 
 A single-center, open-label, prospective, and off-on-off aca-
demic study with a long-term extended follow-up was conducted. 
The study was approved by the Ethics Committee of the Clinical 
Research Center and was conducted in accordance with the EU 
Clinical Trial Directive (2001/20/EU), Good Clinical Practice, and 
the Declaration of Helsinki guidelines. Data quality was overseen 
by the study monitors of the Clinical Research Center for Rare Dis-
eases ‘Aldo & Cele Daccò’ of the IRCCS – Istituto di Ricerche 
Farmacologiche ‘Mario Negri’, Bergamo, Italy. The trial is regis-
tered at ClinicalTrials.gov with the Identifier: NCT00309257.
 Participants 
 We included >18-year-old consenting subjects with AS , uri-
nary albumin excretion (UAE) rate persistently >200 μg/min in at 
least two out of three overnight consecutive urine collections, and 
a creatinine clearance >20 ml/min/1.73 m 2 with less than 30% vari-
ations in the three months prior to study entry. Diagnosis of AS 
was based on typical pedigree, clinical features, and biopsy find-
ings in all cases, and it was further confirmed by genetic analyses 
in five. Subjects on treatment with immunosuppressive drugs, 
 vascular disease of the kidney, incomplete bladder emptying, se-
rum K + >5.5 mEq/l despite optimized acid-base balance, and any 
clinically relevant condition that might affect completion of the 
study were excluded as well as breastfeeding or pregnant women, 
or fertile women with ineffective contraception and subjects un-
able to provide an informed consent. Patients who in the investiga-
tors’ judgment could not withdraw any ongoing treatment with 
ACE inhibitors, ARBs, or statins were not considered.
 Baseline Evaluation and Follow-Up 
 After a 4-week wash-out period from ACE inhibitors, ARBs, 
and/or HMGCoA reductase inhibitors and one-week wash-out 
from ndCCBs ( fig. 1 ), potentially eligible patients had a baseline 
evaluation of office BP (the mean of 3 values taken 2 min apart at 
the dominant arm), body weight, routine laboratory tests, over-
night UAE (mean of three measurements in consecutive overnight 
urine specimens collected during the three days before the day vis-
it), and albumin/creatinine (A/C) ratio measurement in spot 
morning urine. Those fulfilling the selection criteria had a baseline 
measurement of their glomerular filtration rate (GFR) and renal 
plasma flow (RPF) by inulin and para-aminohippuric acid renal 
clearance techniques  [6] , respectively. Albumin and IgG fractional 
clearances were also calculated by standard formulas. Then, pa-
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tients entered a study period organized in four consecutive one-
month add-on treatments (month 1: ACE-inhibitor; month 2: 
ARB; month 3: ndCCB; month 4: HMGco inhibitor) followed by 
one-month treatment withdrawal (recovery period). Details about 
treatment doses and stopping rules are provided in the Supple-
mentary material section. At the end of each treatment period and 
of the recovery period, the measurements of clinical and labora-
tory parameters considered at baseline were repeated. GFR, RPF, 
albumin, and IgG fractional clearances were evaluated at the end 
of the four-month treatment period and of the recovery period 
( fig. 1 ). 
 Detailed descriptions of clearance studies, measurements of se-
rum and urinary protein for fractional clearances, and safety eval-
uations are available in the online supplementary material section 
(for all online suppl. material, see www.karger.com/doi/10.1159/ 
000381480).
 Extension 
 After the recovery period, patients were actively followed up 
until July 2014 or until progression to an endpoint (ESRD or last 
available visit for those prematurely withdrawing from the study) 
by 3–6 monthly evaluations of blood pressure, routine laboratory 
tests, including safety parameters, serum lipids, urinary albumin 
excretion, and spot urine A/C ratio ( table  1 ). During this long-
term observation period, all of them were maintained on the same 
treatment regimen that during the treatment period was associated 
with the largest antiproteinuric effect (Month 4,  fig. 1 ).
 Sample Size Estimation 
 On the basis of previous evidence  [13] , in participants with 
non-nephrotic proteinuria (defined as 24 h proteinuria <3.5 g), we 
expected a baseline UAE of approximately 1,000 μg/min and a 70% 
reduction to approximately 300 μg/min at 4 months with a stan-
dard deviation of the differences equal to 600 μg/min. To give the 
study an 80% power to detect as statistically significant (alpha = 
0.05, paired t test, two-tailed test) the expected reduction, 8 pa-
tients with macroalbuminuria had to be included. Patients with 
microalbuminuria identified during the recruitment period could 
also be included as extra-patients.
 Data Analysis 
 The primary efficacy variable was the change in UAE at the end 
of the 4-month treatment period versus baseline . Secondary effi-
cacy variables included changes in UAE, spot morning urinary 
A/C, systolic/diastolic BP, lipid profile, albumin, and IgG fraction-
al clearances and regression from macro- to micro- or normo- al-
buminuria at the end of each 1-month treatment period and of the 
recovery period as compared with baseline.  Safety parameters in-
cluded GFR, RPF, serum creatinine and potassium levels, hemo-
globin concentration, and hematocrit.
 Data are presented as n (%), mean ± standard deviation (SD), 
or median and interquartile range (IQR). Wilcoxon signed-rank 
test or paired  t -test or McNemar test was used for a within-group 
comparison, as appropriate. Longitudinal data analyses of repeat-
ed measures over time were performed using a linear mixed-effects 
model. The UAE and renal hemodynamic and sieving function 
parameters were log-transformed. All p values were two-sided. 
Statistical analyses were performed at the Laboratory of Biostatis-
tics of the Clinical Research Center by using SAS (version 9.1) and 
STATA (version 12).
 Results 
 Nine patients (three men) aged 25–69 (median 34) 
years entered the study from February 24, 2004 to 
 September 9, 2007. At baseline, three of them had heavy 
albuminuria that in two cases was associated with in-
creased serum creatinine levels. Measured GFR was 
 below  normal range (80–120 ml/min/1.73 m 2 ) in five 
–1 0 1 2 3 4 5
Months
Benazepril (10–20 mg/day), n = 9*
*Withdrawn in 1 patient on month 1
Valsartan (80–160 mg/day), n = 9 
Diltiazem (60–120 mg/day), n = 2
Fluvastatin (40–80 mg/day), n = 7
Fluvastatin
(40–80 mg/day),
n = 2
Wash-out Treatment period Recovery
 Fig. 1. Study flowchart. 
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 participants. Three patients were on BP-lowering therapy 
with carvedilol, clonidine alone, or combined with furo-
semide, respectively. No patient was on ACE inhibitor or 
ARB therapy.
 Treatment 
 All participants received the planned doses of benaz-
epril and valsartan ( fig. 1 ), with the exception of one pa-
tient who withdrew the ACE inhibitor at month 1 be-
cause of cough. At month 3, five participants did not re-
ceive diltiazem, because their BP was already in target 
(<120/80 mm Hg) and two because it was contraindi-
cated. As per protocol, these patients received fluvastatin 
from month 3 and the remaining two participants re-
ceived it from month 4. Thus, at month 4, all patients 
were on valsartan and fluvastatin therapy; eight were also 
on benazepril; and two were on diltiazem therapy. Dur-
ing the recovery period, all treatments were withdrawn 
in all participants.
 Carvedilol and clonidine were withdrawn during the 
treatment period. During the recovery period, these treat-
ments were resumed and two additional patients were 
treated with doxazosin since their BP tended to exceed 
the recommended safety target (130/90 mm Hg).
 Overnight Albuminuria and Spot Morning A/C Ratio 
 During the 4-month treatment period, overnight UAE 
progressively declined from a median (IQR) of 657.7 
(292.7–1,089.6) μg/min at baseline to 71.4 (21.7–504.9) 
μg/min at the end of the treatment period (p = 0.009,  ta-
ble  1 ). The UAE significantly declined over 1-month 
benazepril therapy; further progressively decreased 
though months 2 and 3 when treatment with valsartan 
(n  = 9), diltiazem (n = 1), and fluvastatin (n = 8) was 
Table 1.  Patients’ clinical and laboratory parameters at baseline (Month 0), during the treatment (Month 1 to 4) and recovery (Month 5) 
periods, and at the last available follow-up
Month 0 Month 1 Month 2 Month 3 Month 4 Month 5 Last follow-up^
Weight, kg 66.87±12.67 65.94±12.86* 65.88±13.12 66.56±12.86 66.66±13.96 65.73±13.77 67.86±17.83
Systolic BP, mm Hg 138.04±13.96 128.52±10.51** 121.56±15.93** 117.11±14.61** 120.04±10.25** 129.41±8.85* 110.94±20.44***
Diastolic BP, mm Hg 84.3±11.84 75.63±12.68*** 70.70±15.11** 67.3±13.26*** 71.16±11.24*** 79.93±11.73 62.33±11.78***
MAP, mm Hg 102.21±10.88 93.22±10.22*** 87.91±15.06** 84.38±13.35*** 87.51±10.19*** 96.57±9.89 78.53±11.46***
BP <120/80 mm Hg 0 3 (33.3) 4 (44.4) 5 (55.6) 6 (66.7) 2 (22.2) 5 (71.4)***
Hematochemistry
Serum albumin, g/dl 3.43±0.21 3.59±0.28 3.51±0.30 3.62±0.24* 3.51±0.30 3.27±0.27 3.50±0.70
Total protein, g/dl 6.08±0.42 6.20±0.39 6.14±0.42 6.08±0.34 5.92±0.33 5.86±0.31 6.27±0.84
Hb, g/dl 12.58±1.03 12.77±0.95 12.21±1.36 12.01±1.28* 11.82±1.35** 12.09±0.9* 12.31±1.37
Hct, % 37.14±2.82 37.92±2.65 36.44±4.01 35.59±3.06* 35.08±3.14** 35.79±2.09* 37.09±3.41
Potassium, mEq/l 3.89±0.24 4.42±0.43** 4.38±0.57 4.63±0.51** 4.20±0.37* 3.85±0.31 4.53±0.48**
Lipids
Total cholesterol, mg/dl 212±52.46 207.11±41.7 204.22±53.26 164.33±44.42** 148.44±30.81*** 190.56±46.66** 188.50±28.44**
LDL-cholesterol, mg/dl 132.16±40.04 117.84±43.26 125.29±33.04 95.16±29.62** 84.84±25.84*** 115.44±33.35** 106.50±21.70*
HDL cholesterol, mg/dl 56.11±18 59.33±18.95 50.22±9.73 48.78±11.94* 46.11±11.58*** 49.44±12.6 61.17±7.52
LDL/HDL cholesterol 2.51±0.92 2.21±0.98 2.58±0.82 2.04±0.66 1.88±0.46* 2.43±0.76 1.75±0.35*
Tryglicerides, mg/dl 117.89±62.95 156.67±131.25 151.33±175.74 107±71.92 87.11±43.84 120±68.31 105.17±50.22
Renal function parameters
Serum creatinine, mg/dl 1.21±0.8 1.32±0.98 1.33±0.88* 1.42±1.08 1.39±0.92** 1.37±1.13 0.90±0.40
A/C spot 2.05±1.39 1.48±0.58 0.64±0.84* 0.55±0.86** 0.65±0.61* 0.98±0.37* 0.61±0.55*
Median 1.91 1.59 0.27 0.22 0.42 1.08 0.34
IQR 1.57–2.11 1.14–1.89 0.23–0.58 0.18–0.39 0.23–1.09 0.9–1.25 0.23–1.11
Overnight UAE, μg/min 819.17±734.27 545.25±517.92* 476.06±666.18** 317.24±579.72** 349.97±522.38** 629.41±712.98 349.10±452.56
Median 657.66 348.87 114.98 76.18 71.45 404.3 89.12
IQR 292.67–1,089.6 281.03–574.0 45.77–510.02 32.17–291.23 21.67–504.88 167.95–446.76 34.78–590
UAE 20–200 μg/min 1 (11.1) 2 (22.2) 4 (44.4) 4 (44.4) 3 (33.3) 3 (33.3) 3 (42.8)
UAE <20 μg/min 0 0 1 (11.1) 1 (11.1) 3 (33.3) 0 1 (14.3)
 Data are mean ± SD, median (IQR) or number (%). * p < 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs. month 0. ^ Include data of the 7 patients on active follow-up 
who did not reach end stage renal disease.
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 added on, respectively; and finally stabilized during 
month 4 while all participants were on fluvastatin (linear 
mixed-effects model from baseline to month 4: p = 0.001). 
Then, the UAE approximated baseline values at the end 
of the recovery period after all study drugs had been with-
drawn for 1 month ( table 1 ;  fig. 2 , upper panel). At the 
end of the four-month treatment period, out of the eight 
participants with macroalbuminuria at inclusion, three 
had regressed to microalbuminuria and three had re-
gressed to normoalbuminuria (McNemar’s test, p = 0.025 
vs. baseline). At the end of the recovery period, no par-
ticipant was normoalbuminuric any longer, three were 
microalbuminuric, and six were macroalbuminuric ( ta-
ble 1 ). The participant with microalbuminuria at inclu-
sion was persistently microalbuminuric throughout the 
whole observation period. Albumin/creatinine ratio in 
spot urine samples followed the same trend of UAE ( ta-
ble 1 and  fig. 2 , lower panel).
 Clearance Studies 
 Measured GFR and RPF (or estimated renal blood 
flow), calculated filtration fraction (FF), and measured or 
estimated renal vascular resistances (RVR) did not sig-
nificantly change from baseline to the end of the treat-
ment and recovery periods, whereas albumin and IgG 
fractional clearances significantly declined at the end of 
the treatment period (p = 0.004 and p = 0.005, respec-
tively) and then recovered to baseline values after com-
pletion of the recovery period ( table 2 and  fig. 3 ).
 Other Efficacy Parameters 
 Systolic, diastolic, and mean arterial BP significantly 
and progressively declined throughout the 4-month treat-
ment period and then recovered toward baseline values 
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 Fig. 2. Changes in overnight UAE (upper panel) and spot morning 
urinary A/C ratio during the treatment and recovery phases as 
compared to baseline (month 0). Data are Median (IQR).  *  p < 0.05 
vs. month 0;  * *  p < 0.01 vs. month 0 and 1. 
Table 2.  Renal hemodynamic and sieving function parameters at baseline and at the end of the treatment and recovery periods
Month 0 Month 4 Month 5
GFR, ml/min/1.73 m2 63.27 (50.30–95.36) 72.37 (37.39–91.71) 85.81 (37.73–111.45)
RPF, ml/min/1.73 m2 381.50 (273.81–462.07) 499.35 (181.60–762.78) 452.10 (245.97–546.60)
eRBF°, ml/min/1.73 m2 640.10 (402.66–740.50) 784.49 (279.88–1,181.53) 684.51 (397.30–845.05)
FF (%) 17.75 (11.81–21.50) 14.00 (12.14–17.33) 18.29 (13.34–19.86)
RVR 0.24 (0.22–0.35) 0.18 (0.12–0.58) 0.21 (0.18–0.57)
ERVR°° 0.15 (0.13–0.23) 0.11 (0.08–0.37) 0.14 (0.12–0.35)
Alb Fract. Clear. (×10–5) 66.88 (53.63–80.84) 9.38 (4.59–25.96)* 47.73 (35.16–59.65)
IgG Fract. Clear (×10–5) 5.10 (3.03–8.44) 1.07 (0.55–3.17)* 3.08 (2.28–5.03)
 Data are mean ± SD or median (IQR). * p < 0.01 vs. month 0.
° eRBF = RPF/(1-hematocrit), °° eRVR = MAP/eRBF.
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after treatment withdrawal ( table  1 ). At the end of the 
treatment period, 6 patients had their BP reduced to 
<120/80 mm Hg compared with none at baseline . Total 
and LDL cholesterol levels showed a similar trend to pro-
gressively decline during the treatment period and par-
tially recovered after treatment withdrawal. HDL choles-
terol followed a similar trend; changes, however, were 
smaller than for LDL cholesterol. Thus, LDL/HDL choles-
terol progressively declined during the treatment period 
and then recovered to baseline values at the study end. No 
appreciable changes were observed in serum triglycerides, 
total proteins, and serum albumin levels ( table 1 ).
 Sensitivity Analyses 
 All considered outcome data did not change apprecia-
bly when statistical analyses were performed without 
considering the patient with microalbuminuria at inclu-
sion (data not shown).
 Extension 
 After the completion of the recovery period, one pa-
tient declined his consensus to continued treatment ac-
cording to the Remission Clinic program and was lost to 
follow-up. One of the eight patients maintained on active 
follow-up progressed to ESRD at 57 months after inclu-
sion. His baseline creatinine and urine spot A/C ratio 
were 2.41 mg/dl and 1.67, respectively. At 105 (IQR: 92–
123) months of follow-up, the other seven patients still 
had normal kidney function. At final visit, their median 
UAE and spot urine A/C ratio were similar to those ob-
served at the end of the treatment period (month 4,  ta-
ble 1 and  fig. 2 ). Three of these patients had regressed to 
microalbuminuria and one had regressed to normoalbu-
minuria ( table 1 ).
 Safety 
 No patients had acute renal function deterioration, hy-
perkalemia (serum potassium >5.5 mEq/l), or any other 
treatment-related serious adverse event throughout the 
whole observation period. One patient stopped benaz-
epril therapy at month 1 because of cough, while no pa-
tient withdrew fluvastatin because of muscle/liver toxic-
ity. Hemoglobin concentration and hematocrit levels 
slightly but significantly decreased at months 3 and 4 
compared to baseline and only partially recovered after 
treatment withdrawal. Serum potassium increased dur-
ing the treatment period and then recovered to baseline 
values at the end of the study.
 Discussion 
 In this prospective, open-label, single arm, and off-on-
off cohort study, we found that a multidrug treatment 
titrated to urinary albumin – the Remission Clinic proto-
col – safely and remarkably reduced both overnight albu-
minuria, the primary efficacy variable of the study, and 
A/C ratio in spot morning urine in 9 albuminuric patients 
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 Fig. 3. Albumin (left panel) and IgG (right panel) fractional clearances at baseline and at the end of the 4-month 
treatment period and of the recovery period. Data are median (IQR). 
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with AS. We observed a progressively incremental anti-
proteinuric effect during the four-month treatment pe-
riod that weaned after treatment withdrawal. Changes in 
albuminuria and A/C ratios considered as continuous 
variables were paralleled by a progressive regression from 
macroalbuminuria to micro- or even normo albuminuria 
in six participants at the end of the treatment period. Of 
note, the treatment effect was consistent in all study par-
ticipants, including those with heavy albuminuria and 
more severe renal insufficiency and the one single patient 
who was microalbuminuric at inclusion. Findings that di-
rectly measured RPF and GFR did not change apprecia-
bly, whereas albumin and IgG fractional clearances re-
markably decreased during the treatment period, provid-
ed the evidence that the antiproteinuric effect of the 
Remission Clinic regimen could not be explained by im-
paired kidney perfusion and filtration, but rather reflect-
ed a clinically relevant amelioration of the glomerular 
sieving dysfunction possibly mediated by decreased in-
tracapillary pressure  [14] and/or improved glomerular 
barrier size selectivity  [15] . Independent of mechanism(s), 
these changes are expected to blunt the ultrafiltration of 
plasma macromolecules, with amelioration of protein 
traffic, prevention of protein nephrotoxicity, and protec-
tion from progressive kidney damage and function loss 
 [16] .
 Consistently, over the ten-year study duration, seven 
out of the eight patients who accepted to enter the exten-
sion, long-term treatment period according to the Remis-
sion Clinic protocol retained normal renal function, with 
three patients regressing to microalbuminuria and one to 
normoalbuminuria. The remaining patient who already 
had severe renal insufficiency and overt proteinuria at 
study inclusion eventually progressed to ESRD. Thus, at 
variance with previous evidence that AS patients with 
macroalbuminuria progress to ESRD by the age of 40 
while on ACE inhibitor monotherapy  [3] , our present 
findings confirm that, even at the stage of overt nephrop-
athy, an antiproteinuric approach based on maximized 
RAS inhibition with ACE inhibitors and ARB combina-
tion therapy  [8] may halt disease progression – at least in 
those without severe renal insufficiency to start with – 
and may even achieve remission of proteinuria in a sub-
stantial proportion of cases.
 Treatment was safe and well tolerated. Only one pa-
tient stopped ACE inhibitor therapy because of cough 
during the treatment period. Serum potassium levels nev-
er exceeded 5.5 mEq/l. Thus, treatment is cautiously and 
gradually up-titrated in parallel with close BP and serum 
potassium monitoring, the Remission Clinic approach 
can be safely applied to patients with the AS, including 
those with more advanced renal disease. Importantly, pa-
tients continued RAS inhibition at the maximal tolerated 
doses for more than 6 years with no major adverse effect.
 Limitations and Strengths 
 This was a small study with no control group. The rar-
ity of the clinical condition prevented identifying enough 
patients to design a randomized parallel group study 
comparing the Remission Clinic regimen with ACE in-
hibitor monotherapy, especially in the context of a single-
center and resource-limited, fully academic study .  We at-
tempted to overcome this limitation by designing a lon-
gitudinal study organized in a step-by-step treatment 
period preceded and followed by run-in and recovery off-
treatment periods. With this already described approach 
 [6] , each included patient served as his/her-own control. 
Even more important, finding that after inclusion into the 
extension phase of the study both albuminuria and spot 
urine A/C ratio again decreased to levels observed at com-
pletion of the treatment period provided definite evi-
dence of a causal relationship between treatment and ob-
served outcomes, including long-term protective effects 
against renal disease progression. Thus, intra-patient 
comparisons avoided inter-patient variability, which al-
lowed adequately powered analyses despite the small 
sample size. The use of values of albuminuria averaged 
from measurements in three consecutive overnight urine 
collections minimized the confounding effect of random 
data fluctuations. The use of gold standard procedures for 
the direct measurement of GFR and RPF by inulin and 
PAH clearances, respectively, and the concomitant mea-
surement of albumin and IgG fractional clearances were 
additional strengths. These data may be particularly rel-
evant, since renal hemodynamics and sieving function 
has never been evaluated in the context of the Remission 
Clinic protocol. No previous study had evaluated the ef-
fect of this approach over such a long observation period.
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